The latest Association Française pour l’Etude du Foie – French Association for Study of the Liver (AFEF) and European Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV).
As part of this announcement, AFEF proposes FibroScan® or complex fibrosis biological tests thresholds, to rule out the diagnosis of severe fibrosis and therefore to identify patients who will not require prolonged follow-up. This further re-establishes the validity and importance of the Fibroscan testing. As per their announcement: “FibroScan® (transient elastography) that measures liver stiffness in a non-invasive way is an educational and motivational tool for AFEF, qualities that were confirmed in several experiments available in addiction centers[9–11].”
You can read the full guidelines here.